此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

A Trial of SHR3162 in Healthy Caucasian Volunteers

2022年7月13日 更新者:Atridia Pty Ltd.

A Phase 1, Open-Label, Two-Center Study to Evaluate the Safety and Pharmacokinetics of Single-Dose Fluzoparib in Healthy

The purpose of this study is to assess the safety and PK characteristics of a single oral dose of fluzoparib in healthy Caucasian and Chinese subjects

研究概览

地位

完全的

干预/治疗

研究类型

介入性

注册 (实际的)

12

阶段

  • 阶段1

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

    • New South Wales
      • Sydney、New South Wales、澳大利亚、2000
        • Atridia Pty Limited

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 至 45年 (成人)

接受健康志愿者

是的

有资格学习的性别

全部

描述

Inclusion Criteria:

  1. Healthy Caucasian subjects, male and female, 18 to 45 years of age, inclusive, and in good health as determined by past medical history, physical examination, vital signs, electrocardiogram, and laboratory tests;
  2. Male body weight ≥50 kg, female body weight ≥45 kg, body mass index (BMI) between ≥18.0 and ≤29.0 kg/m2, inclusive;
  3. Female subjects agree not to be pregnant or lactating from beginning of the study screening to 90 days after trial completion:

    • A negative blood and urine pregnancy test for females of childbearing potential at Screening and at Check-in, respectively;
    • Females of reproductive potential are willing and able to employ a highly effective method of birth control/contraception to prevent pregnancy; A highly effective method of contraception is defined as one that results in a low failure rate (ie, less than 1% per year), when used consistently and correctly. Females of non-childbearing potential will not be required to use contraception. Females of non-child bearing potential are defined as permanently sterile (eg, due to hysterectomy) or postmenopausal (defined as at least 12 months following cessation of menses without an alternative medical cause and serum FSH levels >25 IU/L).
  4. Males agree to refrain from donating sperm and fathering a child during the study and for at least 90 days after fluzoparib administration; male participants must agree to remain abstinent or must ensure a condom is used for all sexual activity (with a male or female partner) for this same duration.
  5. Able and willing to refrain from caffeine or caffeine-containing products, alcohol, fruit juices, and smoking/tobacco products from at least 48 hours prior to Check-In until the end of Safety Follow Up;
  6. Able and willing to refrain from eating and drinking poppy seed-containing products and grapefruit-related citrus fruits (eg, Seville oranges, pomelos) within 7 days prior to dosing until after collection of the final PK blood sample (Day 4);
  7. Able and willing to refrain from strenuous exercise (heavy lifting, weight training, calisthenics, aerobics) within 7 days prior to dosing until after collection of the final PK blood sample (Day 4);
  8. Willing and able to comply with all scheduled visits, study procedures, and provides written informed consent.

Exclusion Criteria:

  1. Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, neuropsychiatric disease, or any condition that may affect drug absorption, distribution, metabolism, and excretion;
  2. Had a severe infection, trauma or major surgery within 4 weeks of screening and at Check-In; plan to have a surgery during the trial;
  3. A past medical history of ECG abnormalities, documented cardiac arrhythmias, or cardiovascular disease; or QTcF interval >450 msec for males, >470 msec for females, or <300 msec;
  4. Subject's systolic blood pressure (SBP) is >140 or <90 mmHg, diastolic blood pressure (DBP) is >90 or <50 mmHg, resting heart rate <40 or >100 bpm, and respiratory rate <10 or >20 breaths/min at Screening or Check-in after resting in a semi-supine position for 5 minutes. Vitals can be repeated twice (a minimum of 1 to 2 minutes apart) based on the investigator's judgment;
  5. History of immunodeficiency including seropositivity for human immunodeficiency virus (HIV), or other acquired or congenital immune-deficient disease, or any active systemic viral infection requiring therapy (eg, hepatitis B or C);
  6. Subject has a history of type 1 hypersensitivity to any medication;
  7. Subject has evidence of substance abuse, a history of substance abuse, or is positive for drugs of abuse (eg, methamphetamines, opiates, methadone, cocaine, amphetamines, cannabinoids, tricyclic antidepressants, phencyclidine, barbiturates, benzodiazepines), or alcohol at Screening and Check-in (Day -1);
  8. History of symptomatic hypoglycemia;
  9. Subjects who smoke more than 5 cigarettes per day or will not refrain from smoking starting from at least 48 hours prior to screening and check-in on Day -1, and during the study;
  10. History of regular alcohol consumption in the past 3 months exceeding an average weekly intake of 14 standard drinks; 1 drink=5 ounces [150 mL] of wine or 12 ounces [360 mL] of beer or 1.5 ounces [45 mL] of hard liquor;
  11. Subject has used prescription medications within 14 days or, as per PI discretion, over-the-counter medications, dietary/nutritional supplements (except hormonal contraceptives, paracetamol under 2 grams/day, vitamin supplements) within 7 days or 5 half-lives prior to fluzoparib administration;
  12. Treatment with an investigational drug within 3 months (or 5 half-lives, whichever is longer) of dosing;
  13. Use of medications affecting liver metabolism within 1 month of screening;
  14. Blood donation or loss of more than 200 mL of blood within 1 month of screening; or blood donation or loss of more than 400 mL of blood within 3 months of screening; or received blood within 8 weeks of screening;
  15. Any other major illness/condition that, in the investigator's judgment, substantially increased the risk associated with the subject's participation in and completion of the study or could preclude the evaluation of the subject's response.

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:不适用
  • 介入模型:单组作业
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
实验性的:Dose level 1
Will enroll a single cohort of 12 healthy Caucasian subjects with an approximately one-to-one ratio of male to female subjectssubjects can be enrolled and dosed simultaneously.
Fluzoparib, also known as SHR3162, is an inhibitor of human PARP
其他名称:
  • Fluzoparib

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Pharmacokinetic - Cmax
大体时间:Pre-dose, 0.25, 0.5, 1, 1.5, 2 , 3, 4, 6, 8, 10, 24, 48, and 72 hr post-dose
Maximum observed plasma concentration (Cmax) of SHR3162
Pre-dose, 0.25, 0.5, 1, 1.5, 2 , 3, 4, 6, 8, 10, 24, 48, and 72 hr post-dose
Pharmacokinetic - AUC∞
大体时间:Pre-dose, 0.25, 0.5, 1, 1.5, 2 , 3, 4, 6, 8, 10, 24, 48, and 72 hr post-dose
Area under the concentration-time curve from time 0 to infinity of SHR3162
Pre-dose, 0.25, 0.5, 1, 1.5, 2 , 3, 4, 6, 8, 10, 24, 48, and 72 hr post-dose
Pharmacokinetic - Tmax
大体时间:Pre-dose, 0.25, 0.5, 1, 1.5, 2 , 3, 4, 6, 8, 10, 24, 48, and 72 hr post-dose
Time to Cmax of SHR3162
Pre-dose, 0.25, 0.5, 1, 1.5, 2 , 3, 4, 6, 8, 10, 24, 48, and 72 hr post-dose
Pharmacokinetic - CL/F
大体时间:Pre-dose, 0.25, 0.5, 1, 1.5, 2 , 3, 4, 6, 8, 10, 24, 48, and 72 hr post-dose
Apparent clearance of SHR3162
Pre-dose, 0.25, 0.5, 1, 1.5, 2 , 3, 4, 6, 8, 10, 24, 48, and 72 hr post-dose
Pharmacokinetic - Vz/F
大体时间:Pre-dose, 0.25, 0.5, 1, 1.5, 2 , 3, 4, 6, 8, 10, 24, 48, and 72 hr post-dose
Apparent volume of distribution during terminal phase of SHR3162
Pre-dose, 0.25, 0.5, 1, 1.5, 2 , 3, 4, 6, 8, 10, 24, 48, and 72 hr post-dose
Pharmacokinetic - t1/2
大体时间:Pre-dose, 0.25, 0.5, 1, 1.5, 2 , 3, 4, 6, 8, 10, 24, 48, and 72 hr post-dose
Terminal elimination half-life of SHR3162
Pre-dose, 0.25, 0.5, 1, 1.5, 2 , 3, 4, 6, 8, 10, 24, 48, and 72 hr post-dose

次要结果测量

结果测量
措施说明
大体时间
Adverse events
大体时间:Screening up to study completion, approximately 5 weeks
Number of subjects with adverse events (AEs)
Screening up to study completion, approximately 5 weeks
Laboratory results
大体时间:Screening up to study completion, approximately 5 weeks
Number of subjects with laboratory tests findings of potential clinical importance
Screening up to study completion, approximately 5 weeks
Vital signs
大体时间:Screening up to study completion, approximately 5 weeks
Incidence of vital sign abnormalities
Screening up to study completion, approximately 5 weeks
Electrocardiogram
大体时间:Screening up to study completion, approximately 5 weeks
Number of subjects with clinically significant abnormal ECG QT Interval
Screening up to study completion, approximately 5 weeks

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2020年4月17日

初级完成 (实际的)

2020年5月15日

研究完成 (实际的)

2020年6月30日

研究注册日期

首次提交

2020年4月1日

首先提交符合 QC 标准的

2020年4月1日

首次发布 (实际的)

2020年4月3日

研究记录更新

最后更新发布 (实际的)

2022年7月14日

上次提交的符合 QC 标准的更新

2022年7月13日

最后验证

2020年7月1日

更多信息

与本研究相关的术语

其他研究编号

  • SHR3162-I-113

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅